-
Product Insights
New![]()
Net Present Value Model: Regeneron Pharmaceuticals Inc’s Itepekimab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Regeneron Pharmaceuticals Inc’s Fianlimab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Regeneron Pharmaceuticals Inc's Fianlimab Drug Details: Fianlimab is under development for the treatment of metastatic melanoma, acral lentiginous melanoma, non-small cell lung cancer,...
-
Product Insights
New![]()
Net Present Value Model: Regeneron Pharmaceuticals Inc’s Linvoseltamab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Regeneron Pharmaceuticals Inc’s Odronextamab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Regeneron Pharma – Raheen Biopharmaceutical Manufacturing Plant – Munster
Equip yourself with the essential tools needed to make informed and profitable decisions with our Regeneron Pharma - Raheen Biopharmaceutical Manufacturing Plant - Munster report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Regeneron Pharma – Preclinical Manufacturing Facility Expansion – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our Regeneron Pharma - Preclinical Manufacturing Facility Expansion - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Regeneron Pharma – Tarrytown Life Sciences Headquarters Expansion – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our Regeneron Pharma - Tarrytown Life Sciences Headquarters Expansion - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Regeneron Pharma – 555 Saw Mill River Road Research and Development Campus Expansion – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our Regeneron Pharma - 555 Saw Mill River Road Research and Development Campus Expansion - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report?...
-
Company Profile
![]()
Regeneron Pharmaceuticals Inc – Company Profile
Regeneron Pharmaceuticals Inc (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REGN-7075 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.REGN-7075 in Solid Tumor Drug Details:REGN-7075 in combination with Libtayo (cemiplimab) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REGN-7075 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.REGN-7075 in Non-Small Cell Lung CancerDrug Details:REGN-7075 in combination with Libtayo (cemiplimab) is under development for the...
-
Product Insights
New![]()
Net Present Value Model: Gritstone Bio Inc’s GRANITE-001
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s V-116
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Davutamig in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Davutamig in Non-Small Cell Lung CancerDrug Details:Davutamig (REGN-5093) is under development for the treatment of MET-altered...
-
Product Insights
New![]()
Net Present Value Model: Plus Therapeutics Inc’s Rhenium (186Re) Obisbemeda
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
Regeneron Pharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023
Regeneron Pharmaceuticals Inc (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-1942 in Treatment Resistant Depression
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-1942 in Treatment Resistant Depression Drug Details: MK-1942 is under development for treatment of Alzheimer's...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ITI-333 in Depression
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ITI-333 in Depression Drug Details: ITI-333 is under development for the treatment of opioid use...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gavocabtagene Autoleucel in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gavocabtagene Autoleucel in Non-Small Cell Lung Cancer Drug Details: TC-210 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REGN-9933 in Venous Thromboembolism
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REGN-9933 in Venous Thromboembolism Drug Details: REGN-9933 is under development for the prevention of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.